Skip to main content

Table 3 Univariate and multivariate analysis of factors associated with positive anti-SARS-CoV-2 antibodies

From: Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival

  IgM/IgG Univariable   Multivariable  
  Negative Positive OR 95% CI P OR 95% CI P
Sex
 Males, n (%) 1891 (61.5) 117 (60.6) 0.96 0.72–1.30 0.82    
City of residence
 Guadalupe, n (%) 1846 (60.0) 124 (64.2) 1.20 0.89–1.62 0.26    
Occupation
 Police, firefighters & public safety, n (%) 982 (31.9) 69 (35.8) 1.19 0.88–1.61 0.27    
 Office/Management, n (%) 660 (21.5) 36 (18.7) 0.84 0.58–1.21 0.41    
 Cleaning/Mantainance, n (%) 583 (18.9) 25 (12.9) 0.64 0.41–0.98 0.04 0.71b 0.46–1.10 0.13
 Health-care workers, n (%) 155 (5.0) 8 (4.1) 0.82 0.40–1.68 0.73    
 Other, n (%) 695 (22.7) 55 (28.6) 1.37 0.99–1.89 0.06    
Comorbidities
 Hypertension, n (%) 269 (8.7) 18 (9.3) 1.07 0.65–1.77 0.79    
 Diabetes, n (%) 273 (8.9) 14 (7.3) 0.80 0.46–1.40 0.51    
 Obesity, n (%) 1164 (37.9) 77 (39.9) 1.09 0.81–1.47 0.59    
 Any comorbiditiea, n (%) 1481 (48.2) 100 (51.8) 1.16 0.87–1.55 0.34    
COVID-19 symptoms
 Asymptomatic, n (%) 2627 (85.4) 114 (59.1) 0.25 0.18–0.33  < 0.001    
 Symptomatic, n (%) 448 (14.6) 79 (40.9) 4.06 2.99–5.51  < 0.001 3.91b 2.86–5.35  < 0.001
 Cough, n (%) 119 (3.9) 47 (24.4) 7.98 5.49–11.65  < 0.001 4.17c 2.50–6.93  < 0.001
 Sore throat, n (%) 202 (6.6) 33 (17.1) 2.93 1.96–4.38  < 0.001    
 Nasal discharge, n (%) 85 (2.8) 15 (7.8) 2.97 1.68–5.24 0.001    
 Shortness of breath, n (%) 40 (1.3) 21 (10.9) 9.26 5.34–16.06  < 0.001    
 Headache, n (%) 173 (5.6) 32 (16.6) 3.33 2.21–5.02  < 0.001    
 Anosmia, n (%) 63 (2.0) 40 (20.7) 12.62 8.22–19.37  < 0.001 5.75c 3.41–9.71  < 0.001
 Diarrhea, n (%) 92 (3.0) 23 (11.9) 4.39 2.71–7.12  < 0.001    
 Muscle pain, n (%) 98 (3.2) 31 (16.1) 5.81 3.77–8.97  < 0.001    
 Fever, n (%) 62 (2.0) 29 (15.0) 8.59 5.38–13.72  < 0.001 2.44c 1.30–4.58 0.006
 Contact with confirmed case, n (%) 416 (13.5) 39 (20.2) 1.62 1.12–2.34 0.013    
  1. aOther cardiovascular, allergic, endocrine, and neurological diseases. bAdjusted for cleaning/maintenance, symptoms, and contact with a confirmed case. cAdjusted for contact with a confirmed case, cleaning/maintenance, sore throat, and headache. OR Odds ratio, CI Confidence interval